{{Short description|Canadian biotechnology company}} {{Infobox company | name = Zymeworks Inc. | logo = File:Zymeworks Logo 2024.png | logo_size = 200px | type = Public | traded_as = {{NASDAQ|ZYME}} | genre = | fate = | predecessor = | successor = | foundation = 2003 | founder = | defunct = | location_city = Vancouver, British Columbia | location_country = Canada | location = | area_served = | key_people = Kenneth Galbraith (CEO) | industry = Biotechnology | products = Pharmaceuticals | production = | services = | revenue = | operating_income = | net_income = | aum = | assets = | equity = | owner = | parent = | num_employees = 275 | divisions = | subsid = | homepage = {{URL|http://www.zymeworks.com/}} | footnotes = | intl = }}
'''Zymeworks''' '''Inc.''' is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.<ref>{{cite web | date=April 12, 2012 | url=http://zymeworks.com/about/index.html | title=About Zymeworks | access-date=2012-04-12 | archive-date=2012-04-08 | archive-url=https://web.archive.org/web/20120408181230/http://www.zymeworks.com/about/index.html | url-status=dead }}</ref><ref>{{cite journal|last=Holmes|first=David|title=Buy Buy Bispecific Antibodies|journal=Nature Reviews Drug Discovery|year=2011|volume=10|issue=11 |pages=798–800|doi=10.1038/nrd3581|pmid=22037028|s2cid=27828836 }}</ref><ref>{{cite journal|last=DePalma|first=Angelo|title=Improving Classic Antibody Engineering: Diverse Methodologies and Fresh Insights Turn a Good Technique into an Even Better One|journal=Genetic Engineering and Biotechnology News|year=2011|volume=31|issue=36|doi=10.1089/gen.31.20.14 }}</ref> In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year.<ref name="HT">{{cite web | url=http://www.hottopics.ht/stories/lists/10-healthtech-companies-raised-capital-2014 | title=The 10 healthtech companies that raised the most capital in 2014 | publisher=Hot Topics | date=January 2015 | access-date=14 January 2015 | archive-date=3 May 2015 | archive-url=https://web.archive.org/web/20150503060530/http://www.hottopics.ht/stories/lists/10-healthtech-companies-raised-capital-2014/ | url-status=dead }}</ref> In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade.<ref>{{Cite news|url=https://www.theglobeandmail.com/technology/zymeworks-ipo-bears-good-tidings-for-canadian-biotechnology/article35198952/|title=Zymeworks IPO bears good tidings for Canadian biotechnology|date=2017-06-04|work=The Globe and Mail|access-date=2018-02-20}}</ref> By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.<ref>{{Cite web|url=https://www.bctechnology.com/news/2019/5/17/Zymeworks-and-Pharma-Giant-GSK-Expand-2016-Azymetric-Bispecific-Agreement-Worth-up-to-Potential-US-1.1-Billion.cfm?v=1|title=Zymeworks and Pharma Giant GSK Expand 2016 Azymetric Bispecific Agreement, Worth up to Potential US $1.1 Billion|date=2019-05-17|website=www.bctechnology.com|access-date=2019-10-28}}</ref>
In September 2019, Zymeworks announced that, following their clinical trials, it has been confirmed that their ZW25 monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments.<ref>{{Cite web|url=https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/zymeworks-announces-updated-single-agent-data-for-her2-targeted-bispecific-antibody-zw25-at-european-society-for-medical-oncology-esmo-congress|title=Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress|date=2019-09-28|website=Financial Post|language=en-CA|access-date=2019-10-28}}</ref>
In May 2022, Zymeworks rejected an unsolicited takeover proposal from a Dubai hedge fund, All Blue Falcons FZE, an arm of All Blue Capital.<ref>{{Cite news |last=Silcoff |first=Sean |date=2022-05-20 |title=Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue |language=en-CA |work=The Globe and Mail |url=https://www.theglobeandmail.com/business/article-vancouver-biotech-zymeworks-rejects-1050-per-share-hostile-bid-from/ |access-date=2022-05-20}}</ref>
==Azymetric== This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1.<ref>{{cite web | date=April 19, 2012 | url=http://zymeworks.com/programs/azymetric.html | title=Azymetric | access-date=2012-04-19 | archive-date=2012-05-11 | archive-url=https://web.archive.org/web/20120511204150/http://www.zymeworks.com/programs/azymetric.html | url-status=dead }}</ref><ref>{{Cite journal|doi=10.4161/mabs.25632|pmid = 23924797|pmc = 3851217|title = Improving biophysical properties of a bispecific antibody scaffold to aid developability|journal = mAbs|volume = 5|issue = 5|pages = 646–654|year = 2014|last1 = von Kreudenstein|first1 = Thomas Spreter|last2 = Escobar-Carbrera|first2 = Eric|last3 = Lario|first3 = Paula I.|last4 = d'Angelo|first4 = Igor|last5 = Brault|first5 = Karine|last6 = Kelly|first6 = John F.|last7 = Durocher|first7 = Yves|last8 = Baardsnes|first8 = Jason|last9 = Woods|first9 = R. Jeremy|last10 = Xie|first10 = Michael Hongwei|last11 = Girod|first11 = Pierre-Alain|last12 = Suits|first12 = Michael D. L.|last13 = Boulanger|first13 = Martin J.|last14 = Poon|first14 = David K. Y.|last15 = Ng|first15 = Gordon Y.|last16 = Dixit|first16 = Surjit B.}}</ref> This scaffold can also be engineered with tailored effector function and optimized serum half-life.
==Awards and recognition== * Deal of the Year, Lifesciences BC Awards, 2018<ref>{{Cite web|title=2018 LifeSciences BC Annual Award Winners Announced {{!}} LifeSciences BC|url=https://lifesciencesbc.ca/announcements/2018-lifesciences-bc-annual-award-winners-announced/|access-date=2020-10-09|language=en-CA}}</ref> * Life Sciences Company of the Year, Lifesciences BC Awards, 2016<ref>{{Cite web|title=Zymeworks Receives LifeSciences BC Life Sciences Company of the Year Award|url=https://www.zymeworks.com/news/zymeworks-receives-lifesciences-bc-life-sciences-company-year-award|url-status=dead|archive-url=https://web.archive.org/web/20160624202528/https://www.zymeworks.com/news/zymeworks-receives-lifesciences-bc-life-sciences-company-year-award|archive-date=24 June 2016}}</ref> * Emerging company of the year – Health, BIOTECanada Gold Leaf Awards, 2015<ref>"[http://www.biotech.ca/en/what-we-do/goldleafawards.aspx BIOTECanada :: Gold Leaf Awards] {{Webarchive|url=https://web.archive.org/web/20151003053537/http://www.biotech.ca/en/what-we-do/goldleafawards.aspx |date=2015-10-03 }}". Retrieved 2015-09-17.</ref> * 12th Place, BC's Leading Innovators, 2011<ref>(April 4, 2011). "[http://www.bcbusinessonline.ca/2011/04/04/zymeworks-inc Congratulations to Zymeworks, #12 in 2011's Most Innovative Companies in B.C.] {{Webarchive|url=https://web.archive.org/web/20120412173704/http://www.bcbusinessonline.ca/2011/04/04/zymeworks-inc |date=2012-04-12 }}". Retrieved 2012-04-12.</ref> * Life Science Emerging Rocket, 2009, 2010, 2011<ref>(March 1, 2011) "[http://www.readytorocket.com/2011/03/2011-ready-to-rocket-life-science.html 2011 Ready to Rocket Life Science Presentation]" Retrieved 2012-04-12.</ref> * Early stage Company of the year – Industrial & Agriculture, BIOTECanada Gold Leaf Awards, 2009<ref>"[http://biotech.atomicmotion.com/uploads/2009annualreport.pdf 2009 BIOTECanada Annual Report] {{Webarchive|url=https://web.archive.org/web/20160303224422/http://biotech.atomicmotion.com/uploads/2009annualreport.pdf |date=2016-03-03 }}". Retrieved 2012-04-12.</ref>
==References== {{Reflist}}
{{Authority control}}
Category:Biotechnology companies of Canada Category:Companies based in Vancouver Category:Pharmaceutical companies established in 2003 Category:Pharmaceutical companies of Canada Category:Companies formerly listed on the Toronto Stock Exchange Category:Companies listed on the New York Stock Exchange
{{Canada-company-stub}}